Хірургічне втручання у пацієнтів, які проходять антитромбоцитарну терапію 11 страница

865. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL,­Køber L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of­multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients­following myocardial infarction and coronary intervention: a nationwide cohort­study. Circulation 2012;126(10):1185–1193

866. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr., Bhatt DL, Moliterno DJ,­Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation­undergoing coronary stenting: a North American perspective: executive summary Circulation. Cardiovascular Interventions 2011;4(5):522–534

867. Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P,­Marı´n F. Antithrombotic management of atrial fibrillation patients presenting­with acute coronary syndrome and/or undergoing coronary stenting: executive­summary:a Consensus Document of the European Society of Cardiology­Working Group on Thrombosis, endorsed by the European Heart Rhythm Association­(EHRA) and the European Association of Percutaneous Cardiovascular Interventions­(EAPCI). Eur Heart J 2010;31(11):1311–1318

868. Sarafoff N, Martischnig A,Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple­therapy with aspirin, prasugrel, and vitamin K antagonists in patients with­drug-eluting stent implantation and an indication for oral anticoagulation. J Am­Coll Cardiol 2013;61(20):2060–2066

869. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J Short- and long-termoutcomes with drug-eluting and bare-metal coronary stents:­a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from­randomized trials. Circulation 2012;125(23):2873–2891

870. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,­Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW,­ten Berg JM. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant­therapy and undergoing percutaneous coronary intervention: an openlabel,­randomised, controlled trial. Lancet 2013;381(9872):1107–1115

871. Park S-J, Park D-W, Kim Y-H, Kang S-J, Lee S-W, Lee CW, Han K-H, Park S-W,­Yun S-C, Lee S-G, Rha S-W, Seong I-W, Jeong M-H, Hur S-H, Lee N-H, Yoon J,­Yang J-Y, Lee B-K, Choi Y-J, Chung W-S, Lim D-S, Cheong S-S, Kim K-S, Chae JK,­Nah D-Y, Jeon D-S, Seung KB, Jang J-S, Park HS, Lee K. Duration of dual antiplatelet­therapy after implantation of drug-eluting stents. N Engl J Med 2010;362(15):­1374–1382

872. Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Parise H, Fahy M, Simonton CA,­Sudhir K, Sood P, Smits PC. Stent thrombosis: insights on outcomes, predictors­and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III,­SPIRIT IV and COMPARE trials. EuroIntervention 2012;8(5):599–606

873. Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S. Lack of association­between dual antiplatelet therapy use and stent thrombosis between 1­and 12 months following resolute zotarolimus-eluting stent implantation. Eur­Heart J 2014, published online February 7

874. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K,­Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A,­Kjeldsen K, Storey RF, Pharmacology ESCWGoC, Drug T, Thrombosis­ESCWGo. Expert position paper on the use of proton pump inhibitors in patients­with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34(23):­1708–1713, 1713a–1713b

875. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM,­Pollack C, Gibler WB, Ohman EM, Peterson ED. Excess dosing of antiplatelet­and antithrombin agents in the treatment of non-ST-segment elevation acute coronary­syndromes. JAMA 2005;294(24):3108–3116

876. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De­Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD,­Rao SV, VerheugtFW, Widimsky P, Zeymer U, Collet JP. Bleeding in acute coronary­syndromes and percutaneous coronary interventions: position paper by the­Working Group on Thrombosis of the European Society of Cardiology. Eur­Heart J. 2011;32(15):1854–1864

877. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA,­Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K,­Wojdyla D, Wallentin L. Ticagrelor vs. clopidogrel in acute coronary syndromes­in relation to renal function: results from the Platelet Inhibition and Patient Outcomes­(PLATO) trial. Circulation 2010;122(11):1056–1067

878. Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira A, Amour J, Attar NA,­Ascione R, Taggart D, Collet JP. Expert position paper on the management of antiplatelet­therapy in patients undergoing coronary artery bypass graft surgery. Eur­Heart J 2014;35:1510–1514

879. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, Mazer CD,­Bridges CR, Despotis GJ, Jointer K, Clough ER. 2012 update to the Society of Thoracic­Surgeons guideline on use of antiplatelet drugs in patients having cardiac and­noncardiac operations. The Annals of Thoracic Surgery 2012;94(5):1761–1781

880. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ,­Lenarz LA. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary­artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll­Cardiol 2012;60(5):388–396

881. Varenhorst C, Alstro¨mU, Scirica BM, HogueCW,A°­senblad N, Storey RF, Steg PG,­Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G,­Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor­compared with clopidogrel in patients undergoing coronary artery bypass­surgery. J Am Coll Cardiol 2012;60(17):1623–1630

882. Kwak Y-L, Kim J-C, Choi Y-S, Yoo K-J, SongY, Shim J-K. Clopidogrel responsiveness­regardless of the discontinuation date predicts increased blood loss and transfusion­requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol­2010;56(24):1994–2002

883. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J,­Antonino MJ, Tantry US, Gurbel PA. Platelet function measurement-based strategy­to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary­artery bypass graft surgery: the timing based on platelet function strategy to­reduce clopidogrel-associated bleeding related toCABG(TARGET-CABG) study Circulation. Cardiovascular interventions 2012;5(2):261–269

884. Savonitto S, D’Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M,­Klugmann S, De Servi S. Urgent surgery in patients with a recently implanted coronary­drug-eluting stent: a phase II study of ’bridging’ antiplatelet therapy with tirofiban­during temporary withdrawal of clopidogrel. British Journal of Anaesthesia­2010;104(3):285–291

885. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable­coronary artery disease patients. Int J Cardiol 2000;76(2–3):257–258

886. DeoSV, Dunlay SM, Shah IK, Altarabsheh SE, Erwin PJ, Boilson BA, Park SJ, Joyce LD Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit?­A systematic review and meta-analysis. Journal of Cardiac Surgery 2013;28(2):­109–116

887. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC,­Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H,­Kirtane AJ, Brodie BR, Mehran R, Stuckey TD. Platelet reactivity and clinical outcomes­after coronary artery implantation of drug-eluting stents (ADAPT-DES): a­prospective multicentre registry study. Lancet 2013;382(9892):614–623

888. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P,­Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel­loading and long-termcardiovascular events among patients with acute coronary­syndromes undergoing PCI. JAMA 2011;306(11):1215–1223

889. Breet NJ, vanWerkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH,­Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten­Berg JM. Comparison of platelet function tests in predicting clinical outcome in­patients undergoing coronary stent implantation (POPular Study). JAMA 2010;­303(8):754–762

890. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L,­Sibbing D, Collet JP, Huber K, on behalf of the Working Group on Thrombosis­of the European Society ofCardiology. Expert position paperon the role of platelet­function testing in patients undergoing percutaneous coronary intervention. Eur­Heart J 2014;35(4):209–215

891. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Mu¨ller U, Richardt G,­Jakubowski JA, Neumann F-J. A Randomized Trial of Prasugrel Vs. Clopidogrel in­Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous­Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the­TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent­Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J­Am Coll Cardiol 2012;59(24):2159–2164

892. Collet J-P, Cuisset T, Range´ G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P,­Carrie´ D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monse´gu J,­Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthe´le´my O,­Beygui F, Silvain J,MDEV, Montalescot G. Bedside Monitoring to Adjust Antiplatelet­Therapy for Coronary Stenting. N Engl J Med 2012;367(22):2100–2109

893. Collet J-P, Hulot J-S, Pena A, Villard E, Esteve J-B, Silvain J, Payot L, Brugier D,­Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome­P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial­infarction: a cohort study. Lancet 2009;373(9660):309–317

894. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM,­Braunwald E, Sabatine MS. Genetic variants inABCB1andCYP2C19and cardiovascular­outcomes after treatment with clopidogrel and prasugrel in the TRITONTIMI­38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312–1319

895. Mega JL, Simon T, Anderson JL, Bliden K, Collet JP, Danchin N, Giusti B, Gurbel P,­Horne BD, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG,­Trenk D, Wiviott SD, Sabatine MS. CYP2C19 Genetic Variants and Clinical Outcomes­With Clopidogrel: A Collaborative Meta-Analysis. Circulation 2009;120:­S598-b-9

896. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C,­Schmiebusch P, Bestehorn HP, Bu¨ttner HJ, Neumann FJ. Cytochrome P450­2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated­with adverse 1-year clinical outcome of elective percutaneous coronary­intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:­1925–1934

897. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A,­Marquis JF, O’Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DYF Point-of-care genetic testing for personalisation of antiplatelet treatment­(RAPID GENE): a prospective, randomised, proof-of-concept trial: the RAPID­GENE trial. Lancet 2012 (http://dx.doi.org/10.1016/S0140-6736(12)60161-5)

898. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for­patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol­2005;95(4):509–510

899. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic­events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348(9038):­1329–1339

Не нашли, что искали? Воспользуйтесь поиском: